Global cardiovascular device innovation: Japan-USA synergies - Harmonization by doing (HBD) program, a consortium of regulatory agencies, medical device industry, and academic institutions

Circulation Journal

Volumn 77, Issue 7, 2013, Pages 1714-1718

  Uchida, Takahiro ^a   Ikeno, Fumiaki ^a   Ikeda, Koji ^a   Suzuki, Yuka ^a   Todaka, Koji ^a   Yokoi, Hiroyoshi ^a   Thompson, Gary ^a   Krucoff, Mitchel ^a   Saito, Shigeru ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Cardiovascular devices; Harmonization by Doing; Medical device innovation

Indexed keywords

BIOMEDICAL RESEARCH; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; EQUIPMENT DESIGN; FEMALE; HUMANS; INTERNATIONAL COOPERATION; JAPAN; MALE; MEDICAL DEVICE LEGISLATION; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; UNITED STATES;

EID: 84879398247     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1431     Document Type: Article

References (20)

1. Rao SV, Califf RM, Kramer JM, Peterson ED, Gross TP, Pepine CJ, et al. Postmarket evaluation of breakthrough technologies. Am Heart J 2008; 156: 201-208.
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364: 937-952.
3. Krucoff MW, Brindis RG, Hodgson PK, Mack MJ, Holmes DR Jr. Medical device innovation: Prospective solutions for an ecosystem in crisis: Adding a professional society perspective. JACC Cardiovasc Interv 2012; 5: 790-796.
4. Maisel WH. Innovation at the Food and Drug Administration's Device Center. JACC Cardiovasc Interv 2012; 5: 797-798.
5. Japanese Pharmaceuticals and Medical Device Agency. Incorporated administrative agency: Pharmaceuticals and Medical Devices Agency (PMDA) midterm plan. http://www.pmda.go.jp/english/about/ pdf/e-keikaku.pdf (accessed January 7, 2013).
6. Japanese Pharmaceuticals and Medical Device Agency. Mid-term plan of the pharmaceuticals and medical devices agency. http://www.pmda. go.jp/english/about/pdf/Second_Mid-term_Plan.pdf (accessed January 7, 2013).
7. International Medical Device Regulators Forum. International medical device regulators forum homepage. http://www.imdrf.org/index. asp (accessed January 7, 2013).
8. U.S. Food and Drug Administration. Japan-U.S. "Harmonization By Doing" HBD pilot program initiative. http://www.fda.gov/ MedicalDevices/DeviceRegulationandGuidance/InternationalInformation/ ucm053067.htm (accessed January 7, 2013).
9. Japanese Pharmaceuticals and Medical Device Agency. Japan-US synergies in global medical device innovation: Harmonization by Doing (HBD) at TCT. http://www.pmda.go.jp/hbd/meeting/tct12. html (accessed January 7, 2013).
10. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. Minerva Cardioangiol 2007; 55: 1-18.
11. Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, et al. A prospective, randomized, evaluation of a novel everolimus-eluting coronary stent: The PLATINUM (a Prospective, Randomized Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two De Novo Coronary Artery Lesions) trial. J Am Coll Cardiol 2011; 57: 1700-1708.
12. Kirklin JK, Naftel DC, Stevenson LW, Kormos RL, Pagani FD, Miller MA, et al. INTERMACS database for durable devices for circulatory support: First annual report. J Heart Lung Transplant 2008; 27: 1065-1072.
13. Nakatani T, Sase K, Oshiyama H. 745 Initial Report of Japanese Registry for Mechanically Assisted Circulatory Support (J-MACS). J Heart Lung Transplant 2012; 31(Suppl): S255.
14. Yamazaki K. EVAHEART: Next-generation ventricular assist device. Nippon Rinsho Jpn J Clin Med 2007; 65(Suppl 5): 594-600.
15. Yoshitake I, El-Banayosy A, Yoda M, Hata M, Sezai A, Niino T, et al. First clinical application of the DuraHeart centrifugal ventricular assist device for a Japanese patient. Artif Organs 2009; 33: 763-766.
16. Nakamura M, Kotani J, Kozuma K, Uchida T, Iwabuchi M, Muramatsu T, et al. Effectiveness of paclitaxel-eluting stents in complex clinical patients. Insights from the TAXUS Japan Postmarket surveillance study. Circ J 2011; 75: 2573-2580.
17. Momomura S, Tsutsui H, Sugawara Y, Ito M, Mitsuhashi T, Fukamizu S, et al. Clinical efficacy of cardiac resynchronization therapy with an implantable defibrillator in a Japanese population: Results of the MIRACLE-ICD outcome measured in Japanese indication (MOMIJI) study. Circ J 2012; 76: 1911-1919.
18. U.S. Food and Drug Administration. Collaborative consultation and review of premarketing applications pilot program. http://www.fda.gov/ MedicalDevices/DeviceRegulationandGuidance/International Information/ucm203552.htm (accessed January 7, 2013).
19. Japanese Ministry of Health, Labour, and Welfare. Collaborative consultation and review with the U.S. Food and Drug Administration (in Japanese). http://wwwhourei.mhlw.go.jp/hourei/doc/tsuchi/ T090623I001.pdf (accessed January 7, 2013).
20. Harmonization-by-Doing Working Group 4. Comparing GCP requirements for medical device clinical trials in the US and Japan. Regulatory Focus 2010; 15: 40-44.